Dorothée Duluc
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Dorothée Duluc has a total of 79 co-authors. Here are the top co-authors by number of shared publications:
Patrick Blanco
Unité Mixte de Recherche-Centre National de la Recherche Scientifique 5164, ImmunoConcEpT, Bordeaux University, Bordeaux, France
6 shared publicationsSéverine Loizon
Univ. Bordeaux, CNRS, ImmunoConcEpT, UMR 5164
5 shared publications- Vanja Sisirak
CNRS-UMR 5164, ImmunoConcEpT, Bordeaux University
4 shared publications Jean-François Viallard
The Internal Medicine Department, Groupe Hospitalier Sud, Bordeaux University Hospital, Bordeaux, France
3 shared publicationsAmandine Ferriere
CNRS‐UMR 5164, ImmunoConcEpT Bordeaux University Bordeaux France
2 shared publicationsAnaïs Roubertie
CNRS‐UMR 5164, ImmunoConcEpT Bordeaux University Bordeaux France
2 shared publications
Latest Publications
- Open Access
- 2 July 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17
The plasmacytoid dendritic cell paradox in cancer: impaired type I interferon responses in a nucleic acid–rich tumor microenvironment
Plasmacytoid dendritic cells (pDCs) are specialized immune cells best known for their ability to produce large amounts of type I interferons (IFN-I) upon nucleic acid sensing through endosomal Toll-like receptors (TLR)-7/8 and 9. In tumors, the accumulation of nucleic acids (NAs) deriving from extensive cancer cell death would be expected to activate pDCs and induce IFN-I–mediated anti-tumor responses. However, tumor-infiltrating pDCs typically exhibit impaired IFN-I production and instead acquire immunosuppressive properties, revealing a paradox between NAs availability and pDC function within the tumor microenvironment (TME). In this review, we examine current knowledge and explore the mechanisms that may constrain IFN-I responses by pDCs, including chronic stimulation, alterations in TLR signaling and limited accessibility of tumor-derived NAs. We discuss key open questions regarding how tumor-associated signals may impair pDC responsiveness and contribute to their dysfunction, the nature and immunostimulatory potential of tumor-derived NAs, and their intracellular delivery. By highlighting these unresolved questions, we propose conceptual frameworks to better understand pDC biology in cancer and identify strategies to restore their IFN-I–mediated antitumor functions.
- 2 July 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17
Open AccessThe plasmacytoid dendritic cell paradox in cancer: impaired type I interferon responses in a nucleic acid–rich tumor microenvironment
Plasmacytoid dendritic cells (pDCs) are specialized immune cells best known for their ability to produce large amounts of type I interferons (IFN-I) upon nucleic acid sensing through endosomal Toll-like receptors (TLR)-7/8 and 9. In tumors, the accumulation of nucleic acids (NAs) deriving from extensive cancer cell death would be expected to activate pDCs and induce IFN-I–mediated anti-tumor responses. However, tumor-infiltrating pDCs typically exhibit impaired IFN-I production and instead acquire immunosuppressive properties, revealing a paradox between NAs availability and pDC function within the tumor microenvironment (TME). In this review, we examine current knowledge and explore the mechanisms that may constrain IFN-I responses by pDCs, including chronic stimulation, alterations in TLR signaling and limited accessibility of tumor-derived NAs. We discuss key open questions regarding how tumor-associated signals may impair pDC responsiveness and contribute to their dysfunction, the nature and immunostimulatory potential of tumor-derived NAs, and their intracellular delivery. By highlighting these unresolved questions, we propose conceptual frameworks to better understand pDC biology in cancer and identify strategies to restore their IFN-I–mediated antitumor functions.
- Open Access
Extracellular DNASE1L3 dysfunction fuels obesity-driven inflammation and metabolic syndrome
Obesity, a global health crisis affecting 16% of the world population, is characterized by chronic inflammation that contributes to health complications such as type 2 diabetes and metabolic dysfunction-associated steatotic liver disease (MASLD). Emerging evidence suggests that self-DNA released from dying cells aberrantly activates inflammatory responses during obesity. However, the role of extracellular deoxyribonucleases (DNASEs), which at steady state regulate abundance of extracellular self-DNA, remains poorly understood in this context. Here, we show that individuals with obesity exhibit elevated levels of circulating cell-free DNA (cfDNA) with a distinctive end-motif signature, anti-DNASE1L3 autoantibodies and a reduction in circulating DNASE activity. These cfDNA alterations correlate with the severity of obesity and can be corrected by therapeutic intervention such as bariatric surgery. Similarly, mice fed a high-fat diet (HFD) displayed increased cfDNA levels and decreased DNASE activity. Genetic deficiency of the extracellular nuclease DNASE1L3 in mice worsened HFD-induced metabolic complications, including glucose intolerance, insulin resistance, MASLD, and metabolic tissue inflammation. Conversely, targeted supplementation of DNASE1L3 in the liver using adeno-associated viral vectors protected obese mice from developing MASLD and liver inflammation. These findings uncover a novel role of DNASE1L3 in controlling obesity-associated inflammation and its potential therapeutic use for preventing metabolic disease.
Open AccessExtracellular DNASE1L3 dysfunction fuels obesity-driven inflammation and metabolic syndrome
Obesity, a global health crisis affecting 16% of the world population, is characterized by chronic inflammation that contributes to health complications such as type 2 diabetes and metabolic dysfunction-associated steatotic liver disease (MASLD). Emerging evidence suggests that self-DNA released from dying cells aberrantly activates inflammatory responses during obesity. However, the role of extracellular deoxyribonucleases (DNASEs), which at steady state regulate abundance of extracellular self-DNA, remains poorly understood in this context. Here, we show that individuals with obesity exhibit elevated levels of circulating cell-free DNA (cfDNA) with a distinctive end-motif signature, anti-DNASE1L3 autoantibodies and a reduction in circulating DNASE activity. These cfDNA alterations correlate with the severity of obesity and can be corrected by therapeutic intervention such as bariatric surgery. Similarly, mice fed a high-fat diet (HFD) displayed increased cfDNA levels and decreased DNASE activity. Genetic deficiency of the extracellular nuclease DNASE1L3 in mice worsened HFD-induced metabolic complications, including glucose intolerance, insulin resistance, MASLD, and metabolic tissue inflammation. Conversely, targeted supplementation of DNASE1L3 in the liver using adeno-associated viral vectors protected obese mice from developing MASLD and liver inflammation. These findings uncover a novel role of DNASE1L3 in controlling obesity-associated inflammation and its potential therapeutic use for preventing metabolic disease.
- Open Access
- 30 October 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-9
Inflammasome-targeted therapy might prevent adverse perinatal outcomes of recurrent chronic intervillositis of unknown etiology
Chronic histiocytic intervillositis of unknown origin (CHI) is a rare placental disorder associated with adverse pregnancy outcomes, frequent recurrence, and a lack of effective preventive strategies. Recent insights indicate a potential link between CHI-associated inflammatory lesions and the inflammasome pathway, suggesting innovative therapeutic avenues. Here we show a potential role of the inflammasome pathway in CHI through comprehensive transcriptomic analysis of grade 2 or 3 histopathologic CHI samples, paired with placental controls. Additionally, we present case studies of three individuals with recurrent CHI, who have undergone treatment with anakinra and colchicine throughout pregnancy, resulting in improved perinatal outcomes. Notably, all cases are characterized by the birth of healthy, full-term infants, with reduced or absent intervillositis recurrence. Placental assessment unveils heightened activation of the NLRP3-PYCARD inflammasome pathway and IL-1β processing in CHI samples, with downregulation observed in treated pregnancy samples, devoid of intervillositis. Collectively, these findings suggest a potential therapeutic role for targeting the inflammasome pathway in preventing recurrent CHI in pregnant individuals.
- 30 October 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-9
Open AccessInflammasome-targeted therapy might prevent adverse perinatal outcomes of recurrent chronic intervillositis of unknown etiology
Chronic histiocytic intervillositis of unknown origin (CHI) is a rare placental disorder associated with adverse pregnancy outcomes, frequent recurrence, and a lack of effective preventive strategies. Recent insights indicate a potential link between CHI-associated inflammatory lesions and the inflammasome pathway, suggesting innovative therapeutic avenues. Here we show a potential role of the inflammasome pathway in CHI through comprehensive transcriptomic analysis of grade 2 or 3 histopathologic CHI samples, paired with placental controls. Additionally, we present case studies of three individuals with recurrent CHI, who have undergone treatment with anakinra and colchicine throughout pregnancy, resulting in improved perinatal outcomes. Notably, all cases are characterized by the birth of healthy, full-term infants, with reduced or absent intervillositis recurrence. Placental assessment unveils heightened activation of the NLRP3-PYCARD inflammasome pathway and IL-1β processing in CHI samples, with downregulation observed in treated pregnancy samples, devoid of intervillositis. Collectively, these findings suggest a potential therapeutic role for targeting the inflammasome pathway in preventing recurrent CHI in pregnant individuals.
- Open Access
- 4 April 2024
- Published by Wiley in European Journal of Immunology
- Vol. 54 (6) , e2350903
The deficiency of DNASE1L3 does not affect systemic sclerosis pathogenesis in two inducible murine models of the disease
We induced systemic sclerosis (SSc)-like disease in both wild-type and Dnase1l3-deficient mice using two distinct approaches involving bleomycin and hypochlorous acid injections. Our observations revealed that the deficiency in DNASE1L3 did not affect tissue fibrosis or inflammation caused by these treatments. Despite the association of single nucleotide polymorphisms in humans with SSc pathogenesis, our study demonstrates that DNASE1L3 is dispensable in two inducible murine models of SSc-like pathogenesis.
- 4 April 2024
- Published by Wiley in European Journal of Immunology
- Vol. 54 (6) , e2350903
Open AccessThe deficiency of DNASE1L3 does not affect systemic sclerosis pathogenesis in two inducible murine models of the disease
We induced systemic sclerosis (SSc)-like disease in both wild-type and Dnase1l3-deficient mice using two distinct approaches involving bleomycin and hypochlorous acid injections. Our observations revealed that the deficiency in DNASE1L3 did not affect tissue fibrosis or inflammation caused by these treatments. Despite the association of single nucleotide polymorphisms in humans with SSc pathogenesis, our study demonstrates that DNASE1L3 is dispensable in two inducible murine models of SSc-like pathogenesis.
- Open Access
- 17 November 2023
- Published by Springer Nature in Research Square
Inflammasome-targeted therapy to prevent adverse perinatal outcomes of recurrent chronic histiocytic intervillositis of unknown etiology
Chronic histiocytic intervillositis of unknown origin (CHI) is a rare placental disorder associated with adverse pregnancy outcomes, frequent recurrence, and a lack of effective preventive strategies. Recent insights indicate a potential link between CHI-associated inflammatory lesions and the inflammasome pathway, suggesting innovative therapeutic avenues. This study aims to elucidate the role of the inflammasome pathway in CHI through comprehensive transcriptomic analysis of grade 2 or 3 histopathologic CHI samples, paired with placental controls. Additionally, we present case studies of three individuals with recurrent CHI who received treatment with anakinra and colchicine throughout pregnancy, resulting in improved perinatal outcomes. Notably, all cases led to the birth of healthy, full-term infants, with reduced or absent intervillositis recurrence. Placental assessment unveiled heightened activation of the NLRP3-PYCARD inflammasome pathway and IL-1β processing in CHI samples, with downregulation observed in treated pregnancy samples devoid of intervillositis. Collectively, these findings suggest a potential therapeutic role for targeting the inflammasome pathway in preventing recurrent CHI in pregnant individuals. The molecular insights provided herein open doors for innovative interventions in managing this rare placental disorder, warranting further investigation and consideration.
- 17 November 2023
- Published by Springer Nature in Research Square
Open AccessInflammasome-targeted therapy to prevent adverse perinatal outcomes of recurrent chronic histiocytic intervillositis of unknown etiology
Chronic histiocytic intervillositis of unknown origin (CHI) is a rare placental disorder associated with adverse pregnancy outcomes, frequent recurrence, and a lack of effective preventive strategies. Recent insights indicate a potential link between CHI-associated inflammatory lesions and the inflammasome pathway, suggesting innovative therapeutic avenues. This study aims to elucidate the role of the inflammasome pathway in CHI through comprehensive transcriptomic analysis of grade 2 or 3 histopathologic CHI samples, paired with placental controls. Additionally, we present case studies of three individuals with recurrent CHI who received treatment with anakinra and colchicine throughout pregnancy, resulting in improved perinatal outcomes. Notably, all cases led to the birth of healthy, full-term infants, with reduced or absent intervillositis recurrence. Placental assessment unveiled heightened activation of the NLRP3-PYCARD inflammasome pathway and IL-1β processing in CHI samples, with downregulation observed in treated pregnancy samples devoid of intervillositis. Collectively, these findings suggest a potential therapeutic role for targeting the inflammasome pathway in preventing recurrent CHI in pregnant individuals. The molecular insights provided herein open doors for innovative interventions in managing this rare placental disorder, warranting further investigation and consideration.
- 12 March 2023
- Published by Springer Nature
- Vol. 2618, 173-186
Enrichment of Large Numbers of Splenic Mouse Dendritic Cells After Injection of Flt3L-Producing Tumor Cells
Dendritic cells (DCs) are antigen-presenting cells (APCs) that shape innate and adaptive immunity. There are multiple subsets of DCs distinguished according to their phenotype and functional specialization. DCs are present in lymphoid organs and across multiple tissues. However, their frequency and numbers at these sites are very low making their functional study difficult. Multiple protocols have been developed to generate DCs in vitro from bone marrow progenitors, but they do not fully recapitulate DC complexity found in vivo. Therefore, directly amplifying endogenous DCs in vivo appears as an option to overcome this specific caveat. In this chapter, we describe a protocol to amplify murine DCs in vivo by the injection of a B16 melanoma cell line expressing the trophic factor FMS-like tyrosine kinase 3 ligand (Flt3L). We have also compared two methods of magnetic sorting of amplified DCs, both giving high yields of total murine DCs, but different representation of the main DC subsets found in vivo. Key words Conventional dendritic cells Plasmacytoid dendritic cells Flt3L DC enrichment
- 12 March 2023
- Published by Springer Nature
- Vol. 2618, 173-186
Enrichment of Large Numbers of Splenic Mouse Dendritic Cells After Injection of Flt3L-Producing Tumor Cells
Dendritic cells (DCs) are antigen-presenting cells (APCs) that shape innate and adaptive immunity. There are multiple subsets of DCs distinguished according to their phenotype and functional specialization. DCs are present in lymphoid organs and across multiple tissues. However, their frequency and numbers at these sites are very low making their functional study difficult. Multiple protocols have been developed to generate DCs in vitro from bone marrow progenitors, but they do not fully recapitulate DC complexity found in vivo. Therefore, directly amplifying endogenous DCs in vivo appears as an option to overcome this specific caveat. In this chapter, we describe a protocol to amplify murine DCs in vivo by the injection of a B16 melanoma cell line expressing the trophic factor FMS-like tyrosine kinase 3 ligand (Flt3L). We have also compared two methods of magnetic sorting of amplified DCs, both giving high yields of total murine DCs, but different representation of the main DC subsets found in vivo. Key words Conventional dendritic cells Plasmacytoid dendritic cells Flt3L DC enrichment
- 12 March 2023
- Published by Springer Nature
- Vol. 2618, 3-16
Origin, Phenotype, and Function of Mouse Dendritic Cell Subsets
Dendritic cells are cells of hematopoietic origin that are specialized in antigen presentation and instruction of innate and adaptive immune responses. They are a heterogenous group of cells populating lymphoid organs and most tissues. Dendritic cells are commonly separated in three main subsets that differ in their developmental paths, phenotype, and functions. Most studies on dendritic cells were done primarily in mice; therefore, in this chapter, we propose to summarize the current knowledge and recent progress on mouse dendritic cell subsets’ development, phenotype, and functions. Key words Conventional dendritic cells Plasmacytoid dendritic cells DC ontogeny DC subsets
- 12 March 2023
- Published by Springer Nature
- Vol. 2618, 3-16
Origin, Phenotype, and Function of Mouse Dendritic Cell Subsets
Dendritic cells are cells of hematopoietic origin that are specialized in antigen presentation and instruction of innate and adaptive immune responses. They are a heterogenous group of cells populating lymphoid organs and most tissues. Dendritic cells are commonly separated in three main subsets that differ in their developmental paths, phenotype, and functions. Most studies on dendritic cells were done primarily in mice; therefore, in this chapter, we propose to summarize the current knowledge and recent progress on mouse dendritic cell subsets’ development, phenotype, and functions. Key words Conventional dendritic cells Plasmacytoid dendritic cells DC ontogeny DC subsets
- Open Access
- 25 January 2023
- Published by Oxford University Press (OUP) in Journal of Leukocyte Biology
- Vol. 113 (3) , 305-314
Elevated levels of circulatory follicular T helper cells in chronic lymphocytic leukemia contribute to B cell expansion
Chronic lymphocytic leukemia (CLL) is characterized by an expansion of mature B cells in the bone marrow, peripheral lymphoid organs and blood. CD4 T helper (Th) lymphocytes significantly contribute to the physiopathology of CLL, but the subset(s) of Th cell involved in CLL pathogenesis is (are) still under debate. In this study, we performed flow cytometry analysis of the circulatory T cells of untreated CLL patients and observed an increase in follicular helper T cells (Tfh), which is a subset of T cells specialized in B cell help. Elevated numbers of Tfh cells correlated with disease severity as measured by the Binet staging system. Tfh from CLL patients were activated and skewed toward a Th1 profile as evidenced by their PD-1 + IL-21 + IFNγ+ phenotype and their CXCR3 + CCR6- chemokine receptor profile. Tfh efficiently enhanced B-CLL survival and proliferation through IL-21 but independently of IFNγ. Finally, we observed an inverse correlation between the Tfh1 and IgA and IgG serum levels in patients, suggesting a role for this Tfh subset in the immune dysfunction associated with CLL. Altogether, our data highlight an impairment in circulatory Tfh subsets in CLL patients and their critical role in CLL physiopathology.
- 25 January 2023
- Published by Oxford University Press (OUP) in Journal of Leukocyte Biology
- Vol. 113 (3) , 305-314
Open AccessElevated levels of circulatory follicular T helper cells in chronic lymphocytic leukemia contribute to B cell expansion
Chronic lymphocytic leukemia (CLL) is characterized by an expansion of mature B cells in the bone marrow, peripheral lymphoid organs and blood. CD4 T helper (Th) lymphocytes significantly contribute to the physiopathology of CLL, but the subset(s) of Th cell involved in CLL pathogenesis is (are) still under debate. In this study, we performed flow cytometry analysis of the circulatory T cells of untreated CLL patients and observed an increase in follicular helper T cells (Tfh), which is a subset of T cells specialized in B cell help. Elevated numbers of Tfh cells correlated with disease severity as measured by the Binet staging system. Tfh from CLL patients were activated and skewed toward a Th1 profile as evidenced by their PD-1 + IL-21 + IFNγ+ phenotype and their CXCR3 + CCR6- chemokine receptor profile. Tfh efficiently enhanced B-CLL survival and proliferation through IL-21 but independently of IFNγ. Finally, we observed an inverse correlation between the Tfh1 and IgA and IgG serum levels in patients, suggesting a role for this Tfh subset in the immune dysfunction associated with CLL. Altogether, our data highlight an impairment in circulatory Tfh subsets in CLL patients and their critical role in CLL physiopathology.
- Open Access
- 30 January 2020
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 11, 6
Functions of Tfh Cells in Common Variable Immunodeficiency
Common variable immunodeficiency is the most common clinical primary immunodeficiency in adults. Its hallmarks are hypogammaglobulinemia and compromised B-cell differentiation into memory or antibody-secreting cells leading to recurrent infections. This disease is heterogeneous, with some patients harboring multiple complications such as lymphoproliferative disorders, autoimmune manifestations, or granulomatous inflammation. The mechanisms leading to these complications remain elusive despite numerous associations found in the literature. For instance, although described as a B cell intrinsic disease, numerous abnormalities have been reported in other immune cell compartments. Here, we tuned our attention to follicular helper T cells, a CD4+ T cell population specialized in B cell help, considering the recent publications showing an involvement of these cells in CVID pathogenesis.
- 30 January 2020
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 11, 6
Open AccessFunctions of Tfh Cells in Common Variable Immunodeficiency
Common variable immunodeficiency is the most common clinical primary immunodeficiency in adults. Its hallmarks are hypogammaglobulinemia and compromised B-cell differentiation into memory or antibody-secreting cells leading to recurrent infections. This disease is heterogeneous, with some patients harboring multiple complications such as lymphoproliferative disorders, autoimmune manifestations, or granulomatous inflammation. The mechanisms leading to these complications remain elusive despite numerous associations found in the literature. For instance, although described as a B cell intrinsic disease, numerous abnormalities have been reported in other immune cell compartments. Here, we tuned our attention to follicular helper T cells, a CD4+ T cell population specialized in B cell help, considering the recent publications showing an involvement of these cells in CVID pathogenesis.
- 1 December 2018
- Published by Elsevier in Clinical Immunology
- Vol. 197, 130-138
Increase of follicular helper T cells skewed toward a Th1 profile in CVID patients with non-infectious clinical complications
- 1 December 2018
- Published by Elsevier in Clinical Immunology
- Vol. 197, 130-138
Increase of follicular helper T cells skewed toward a Th1 profile in CVID patients with non-infectious clinical complications